At least 50 children are in remission because of a breakthrough treatment that engineers the body’s own immune system to fight cancer.
By Lesley McClurg, KQED Science
Luxturna, a gene therapy with a list price $850,000, is the latest flashpoint in the debate over how to afford innovative medicines.
By Andrew Joseph, STAT
As the first gene therapies approach the market, drug makers, insurers, and patients are debating complex questions about cost, value, and payment plans.
By Meghana Keshavan, STAT
Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.
By Lauren Neergaard, Associated Press
Science Nation video mapping genomes of alligators crocodiles and bats…
By PBS NewsHour
Dr. Kathy Zoon of the federal Food and Drug Administration oversees the roughly 200 gene therapy clinical trials now underway in the United States.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.